Phase 1/2 trial evaluating intratumoral administration of INT230-6 alone and in combination with an anti-PD1 antibody for advanced malignancies.

Yada Kanjanapan,Nilofer Saba Azad,Lillian L. Siu,Anthony J. Olszanski,Ian B. Walters,Lisa Kamen,Lewis H. Bender,Anthony B. El-Khoueiry

Phase 1/2 trial evaluating intratumoral administration of INT230-6 alone and in combination with an anti-PD1 antibody for advanced malignancies.

2018

Yada Kanjanapan
Nilofer Saba Azad
Lillian L. Siu
Anthony J. Olszanski
Ian B. Walters
Lisa Kamen
Lewis H. Bender
Anthony B. El-Khoueiry

TPS2609Background: INT230-6 is a supermolecular complex of cisplatin, vinblastine, and an amphiphilic penetration enhancer, formulated for intratumoral injection. This agent utilizes technology tha...

Keywords:

Antibody
Pathology
Cancer research
Medicine
anti pd1
penetration enhancer
Cisplatin
Vinblastine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations